Pasithea Therapeutics Corp.
KTTANASDAQHealthcareBiotechnology
Previous close
$0.5394
+$0.0694 · +14.77%
KTTA company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
55
Fair Value
Momentum
18
Strong Down
Sentiment
58
Mixed
Risk resilience
34
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websitePasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions. Founded in 2020, the corporation's primary operations are based in Miami Beach, Florida.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Tiago Reis Marques
- Listed since
- Sep 15, 2021
- Employees
- 5
Market position
Day range
Current $0.5394
52-week range
Current $0.5394
- Open
- $0.489
- Previous close
- $0.47
- Volume
- 302.67K
- 0.46× average
- Average volume
- 660.38K
- Average daily volume
- Market cap
- 18.02M USD
- Beta
- 0.29
- Market reference 1
- 50-day average
- $0.4968
- +8.58% above average
- 200-day average
- $0.7468
- -27.77% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- -46.09M USD
- EV / EBITDA
- 2.28×
- Earnings yield
- -225.22%
- Free cash flow yield
- -167712.31%
Profitability & efficiency
- Return on equity
- -36.99%
- Return on assets
- -33.91%
- Return on invested capital
- -37.74%
Financial health
- Current ratio
- 11.35×
Earnings
- EPS beat rate
- 20%
- 1 beat, 3 misses, 1 met estimate
- Average EPS surprise
- -95.30%
- 5 comparable reports
- Latest EPS result
- -0.16
- Estimate -0.16 · Met by 0.00%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$3.00
456.17% upsidePrice history unavailable
High $3.00Average $3.00Low $3.00KTTA news
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jan 2, 2024 | 1:20 | — | — |
Effective Jan 2, 2024
1:20
KTTA peers
ETFs holding KTTA
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research KTTAresearch.disclaimer